Navigation Links
Nanosys Licenses Nanowire Technology to QuantuMDx Group for Next Generation Diagnostic and Sequencing Technologies
Date:5/11/2009

PALO ALTO, Calif. and LONDON, May 11 /PRNewswire/ --Nanosys Inc. and QuantuMDx Group (QMDx) today announced that QMDx has signed a non-exclusive license agreement with Nanosys for several patents and patent applications related to the use of nanowires for biosensors.

The core intellectual property involves the use of nanowire-based field effect transistors (FETs) as biosensors, which were derived from the work of Dr. Charles Lieber, a professor of chemistry at Harvard, a pioneer in nanotechnology, and one of the founders of Nanosys.

Under terms of the agreement, QMDx has secured worldwide rights for the use of nanowires for DNA sequencing and detecting biomarkers associated with disease. In exchange, Nanosys has received an upfront license fee and downstream royalty payments. No other financial details of the deal were disclosed.

While Nanosys owns an extensive IP portfolio around multiple aspects of nanotechnology including nanowire compositions, nanowire synthesis and the use of nanowires and other nanostructures for diverse applications, QMDx will bring its proprietary molecular biology and microfluidic technologies to bear on using nanowire based field effect transistors (FETs) as highly responsive sensors of biomolecules. The power of Lieber's technology is that it permits accurate diagnosis and quantification of multiple biomarkers using a small biosensor that lends itself to 'Palm Top' diagnostic devices.

QMDx plans to manufacture and sell devices that are formatted to provide fast, accurate and cost effective point-of-care (POC) diagnosis of disease. Furthermore, QMDx plans to develop its DNA sequencing technology with its nanowire biosensors, to enter the genome sequencing market and pioneer the handheld sequencing market.

"Rapid and sensitive biomarker detection, performed at the point of care, at an affordable price point and to standards usually only seen in the referral laboratory will revolutionize care pathways in the developed world and open up a whole new standard of diagnosis in emerging economies," said Elaine Warburton, chief executive officer of QuantuMDx Group Limited. "Whereas present rapid tests still require confirmation in centralized laboratories, our device will negate this need, therefore reducing health costs and significantly improving the care and experience a patient receives."

QuantuMDx Group Limited's chief scientific officer, Jonathan O'Halloran went on to say, "Our proprietary DNA sequencing technology represents a significant step change in the speed, accuracy and read lengths presently available with today's 'next-gen' sequencers. Our patented dual approach to sequence both in parallel and long read lengths, using low cost equipment, will provide the tools necessary for the genomic medicine era."

Andrew Filler, general counsel and vice president of intellectual property at Nanosys, commented, "We are pleased to add QMDx Group as the latest licensee to our broad and deep intellectual property around nanowires for biosensor devices. Through continued R&D and licensing efforts, Nanosys is expanding the transformative applications of nanotechnology in the marketplace."

About Nanosys, Inc.

Nanosys, Inc. is a leader in the development of nanotechnology enabled products utilizing high performance inorganic nanostructures. Nanosys has built one of the broadest technology platforms in the industry with over 650 patents and patent applications covering fundamental areas of nanotechnology. Based in Palo Alto, California and privately held, Nanosys collaborates with industry leaders to develop revolutionary high-value, high-performance products for the life sciences, computing, lighting, renewable energy, and defense industries. Additional information on Nanosys can be found at www.nanosysinc.com.

About QMDx Group

QMDx Group is a U.K.-based biotech company founded by Elaine Warburton, a seasoned healthcare chief executive and Jonathan O'Halloran, a molecular biologist. QMDx is developing and commercializing affordable handheld diagnostic and sequencing technologies based around a nanowire biosensor and innovative microfluidics. The company has offices in the U.K., U.S. and South Africa. Additional information on QMDx can be found at www.quantumdx.com

    For Further Information:
    Nanosys Contact:
    Andrew Filler, general counsel and vice president of intellectual property
    Tel. +1 (650) 331-2176
    Email: afiller@nanosysinc.com

    QMDx Contact:
    Elaine Warburton, chief executive officer
    Tel: +44 791 22 06 106
    Email: elaine.warburton@quantumdx.com


'/>"/>
SOURCE Nanosys Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Global Med Technologies(R) Licenses 90th Site in the Southeastern U.S.
2. Implicit Licenses Clinical Stage Antibody Program From Lilly
3. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
4. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
5. Arizona Heart Innovative Technologies Licenses New Endovascular Device
6. Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
7. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
8. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
9. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
10. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
11. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 2017 Personal Genome Diagnostics Inc. (PGDx) today announced ... Association for Cancer Research (AACR) Annual Meeting 2017, being held ... The company also announced that five scientists associated with PGDx—two ... Annual AACR Team Science Award. ... Doug Ward , CEO ...
(Date:3/29/2017)... Maryland , and HILDEN, Germany , March 29, 2017 ... FRANKFURT PRIME STANDARD: QIA) today announced the U.S. launch ... JAK2 assay), which was cleared by the U.S. Food and Drug Administration ... V617F/G1849T allele in genomic DNA extracted from EDTA whole blood.* ... The ipsogen JAK2 assay is processed on QIAGEN,s ...
(Date:3/29/2017)... ... 2017 , ... (March 29, 2017) — Nerium International ... an active member of the Mexican Direct Selling Association A.C. (AMVD ). ... relationship marketing. This professional organization fosters loyal and fair competition among companies within ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, a ... a quarterly travel award to noteworthy scientists who will be presenting research using ... new round of awards are being given to two postdoctoral fellows studying pathogen ...
Breaking Biology Technology:
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/9/2017)... FRANCISCO and MOUNTAIN VIEW, Calif. ... , "Eating Well Made Simple," and 23andMe , ... help guide better food choices.  Zipongo can now provide ... their food preferences, health goals and biometrics, but also ... certain food choices. Zipongo,s personalized food decision ...
(Date:3/2/2017)... , March 2, 2017 Summary ... better understand Merck KGaA and its partnering interests and ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
Breaking Biology News(10 mins):